5 research outputs found
Indicators which are applied when assessing effects on a body exerted by nitrates and n-nitrosodimethylamine introduced with drinking water
The authors comparatively assessed N-Nitrosodimethylamine (N-NDMA) contents in blood samples taken from children who consumed drinking water with increased nitrates and N-NDMA concentrations and in blood samples taken from children who consumed drinking water which fully corresponded to the existing hygienic standards; the article dwells on the results of this comparative assessment. We detected authentic discrepancies (Ρ<0.005) in N-NDMA contents between blood samples taken from children from the focus group (0.0045 Β± 0.0009 mg/dm3) and the reference one (0.003 Β± 0.0006 mg/dm3). We revealed that free-radical oxidation mechanisms were activated in children from the focus group who were exposed to
N-NDMA. Lipids hydroperoxidation content in blood serum was proved to be 1.6 times higher in children from the focus group than in those from the reference one. When N-NDMA was detected in blood of children from the focus group, they ran 1.73 times higher risks of damages to their cells membranes.
Our assessment of antioxidant protection revealed that glutathione-S-transferase became less active, B12 vitamin content went down, and glutathione peroxidase increased in children from the focus group against those from the reference group; all these parameters were 1.2β1.7 times different between the groups (Ρ = 0.000β0.030). The children from the focus group also ran 2.91 times higher risks of an increase in glutathione peroxidase content.
We detected an authentic cause-and effect relation between an increase in IgG to N-NDMA and growing N-NDMA concentrations in blood (R2 = 0.958, at p = 0.001). Risk of changes occurring in this parameter of humoral immunity was 1.3 times higher in the focus group.
The results of the experimental research allowed us to reveal an increase in fetal proteins (S-CEA and CA 199) contents detected in blood serum of children from the focus group against those from the reference one; the contents were 2.7 and 3.9 times higher correspondingly (Ρ = 0.010β0.023). This increase could be a sign of ongoing processes which characterized tissue proliferation; it could also become a mechanism of uncontrolled cellular proliferation.
The performed research allowed us to substantiate and fix the following biological markers of the effects: an increase in IgG to N-NDMA and in glutathione peroxidase, ASAT activity, and total bilirubin level which can be applied in risk assessment and in giving grounds for permissible concentrations of these toxic compounds in blood
Π‘ΠΠΠ ΠΠ©ΠΠΠΠ«Π ΠΠ£Π Π‘ Β«Π’Π ΠΠΠΠΠΒ» ΠΠ ΠΠ’ΠΠΠΠΠΠ Π£Π‘ΠΠΠ Π’ΠΠ ΠΠΠΠ Π‘ Π’ΠΠΠΠΠ ΠΠΠΠ ΠΠ: ΠΠ ΠΠΠ¦ΠΠΠ« ΠΠ’ΠΠΠ Π ΠΠΠ¦ΠΠΠΠ’ΠΠ
Background: The beginning of a new era of direct acting antivirals sets up its own rules, that is, to achieve the highest efficacy with the shortest duration of treatment. It is assumed that the use of the first generation of direct acting antivirals, similarly to interferon-free regimens, would allow for personalization of approaches to their prescriptions.Aim: To identify the most important parameters that can predict the greatest efficacy of triple antiviral therapy of 12 week duration in patients with chronic hepatitis C genotype 1.Materials and methods: The study included 204 patients with chronic hepatitis C virus (HCV) genotype 1 at an early stage of liver disease (METAVIR score F0-F2), who were either treatment-naive or had a history of relapse after standard of care antiviral therapy. In addition to routine work-up, all patients were screened for IL28B polymorphism; in the course of the treatment viral kinetics was assessed by an ultrasensitive polymerase chain reaction (PCR) (with lower limit of quantification of 12 IU/ml). Duration of the triple therapy (pegylated interferon-Ξ±2a, ribavirin and telaprevir) was reduced to 12 weeks if a rapid virological response was achieved; otherwise the patients continued their treatment in according with guidelines. Results: A complete rapid virological response was achieved in 174 patients (81.6%), in whom the duration of triple therapy was 12 weeks. According to the protocol, 25 patients with a partial rapid virological response continued their standard antiviral therapy for 12 weeks more. In those who achieved a rapid virological response, there was an association between IL28B-CC genotype at rs12979860 and maintenance of zero viremia at 12 weeks after termination of antiviral therapy (r = 0.38, p 0.001). In all such patients there was a stable virological response at 12 weeks of the follow-up. Monitoring of viral load after 14 days of antiviral treatment was not predictive of its success. The preliminary results of a shortened (12 week) course of triple telaprevir-based viral therapy allowed to identify the most significant parameters of 100% efficacy, i.e., absence of the virus in blood at 12 weeks after termination of antiviral therapy. Conclusion: A 12 week course of triple telaprevir-based combination therapy is an optimal regimen for achievement of a stable virological response after 12 weeks of the follow-up in treatment-naΓ―ve patients with HCV genotype 1 or with a relapse after previous conventional antiviral treatment, who have IL28B β CC polymorphism, are at an early stage of liver disease and who achieve a rapid complete virological response confirmed by a highly sensitive PCR.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠ°ΡΡΡΠΏΠ»Π΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΠΎΠΉ ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΏΡΡΠΌΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π΄ΠΈΠΊΡΡΠ΅Ρ ΡΠ²ΠΎΠΈ ΠΏΡΠ°Π²ΠΈΠ»Π° β Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ Π½Π°ΠΈΠΌΠ΅Π½ΡΡΠ΅ΠΉ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΊΡΡΡΠ° Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎ, Π²ΡΡΠΎΠ²Π½ΡΡΡ ΡΠ°Π½ΡΡ Π½Π° ΠΈΠ·Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΏΠ΅ΡΠ²ΡΡ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² β Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΠΎ Π±Π΅Π·ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½ΠΎΠ²ΡΠΌ ΡΡ
Π΅ΠΌΠ°ΠΌ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ β ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ ΠΊ ΠΈΡ
Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ.Π¦Π΅Π»Ρ β ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² Β«ΡΡΠΎΠΉΠ½ΠΎΠΌΒ» ΡΠ΅ΠΆΠΈΠΌΠ΅ Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊΡΡΡΠ° 12 Π½Π΅Π΄Π΅Π»Ρ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ 1-Π³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 204 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ 1-Π³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π½Π° Π½Π°ΡΠ°Π»ΡΠ½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ (F0βF2 ΠΏΠΎ ΡΠΊΠ°Π»Π΅ METAVIR), ΡΠ°Π½Π΅Π΅ Π½Π΅ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ»ΠΈ Ρ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠΌ ΠΏΠΎΡΠ»Π΅ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΠΊΡΡΡΠ° ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ° ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π΅ ΠΊΠ°ΠΆΠ΄ΠΎΠΌΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠΎΠΌΠΈΠΌΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎ-ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° IL28B, Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΠ·ΡΡΠ°Π»ΠΈ Π²ΠΈΡΡΡΠ½ΡΡ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΡ ΡΠ»ΡΡΡΠ°ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ) (Π°Π½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ β 12 ΠΠ/ΠΌΠ»). Π£ΡΠ»ΠΎΠ²ΠΈΠ΅ΠΌ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΠΊΡΡΡΠ° Β«ΡΡΠΎΠΉΠ½ΠΎΠΉΒ» ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (ΠΏΠ΅Π³ΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½ Ξ±2Π°, ΡΠΈΠ±Π°Π²ΠΈΡΠΈΠ½, ΡΠ΅Π»Π°ΠΏΡΠ΅Π²ΠΈΡ) Π΄ΠΎ 12 Π½Π΅Π΄Π΅Π»Ρ Π±ΡΠ»ΠΎ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ Π±ΡΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ°. ΠΡΡΠ°Π»ΡΠ½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°Π»ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΡΡΠΎΠΊΠ°ΠΌΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠ»Π½ΡΠΉ Π±ΡΡΡΡΡΠΉ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΡΠ²Π΅Ρ Π±ΡΠ» Π΄ΠΎΡΡΠΈΠ³Π½ΡΡ Ρ 174 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π΄Π»Ρ ΠΊΠΎΡΠΎΡΡΡ
ΠΊΡΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² Β«ΡΡΠΎΠΉΠ½ΠΎΠΌΒ» ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ» 12 Π½Π΅Π΄Π΅Π»Ρ. ΠΠΎ ΠΈΡΠΎΠ³Π°ΠΌ Π»Π΅ΡΠ΅Π½ΠΈΡ 81,6% Π±ΠΎΠ»ΡΠ½ΡΡ
Π΄ΠΎΡΡΠΈΠ³Π»ΠΈ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. ΠΠΎ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡΠΌ ΠΏΡΠΎΡΠΎΠΊΠΎΠ»Π° 25 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π½Π΅ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ Π±ΡΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΠ»ΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ Π΅ΡΠ΅ 12 Π½Π΅Π΄Π΅Π»Ρ. Π£ Π»ΠΈΡ, Π΄ΠΎΡΡΠΈΠ³ΡΠΈΡ
Π±ΡΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ°, Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠ΅ΠΆΠ΄Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π‘Π‘ IL28B Π² ΠΏΠΎΠ·ΠΈΡΠΈΠΈ rs12979860 ΠΈ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ Π°Π²ΠΈΡΠ΅ΠΌΠΈΠΈ ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ ΠΏΠΎΡΠ»Π΅ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (r = 0,38, p 0,001). Π£ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ΄ΠΎΠ±Π½ΡΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ Π±ΡΠ» Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ ΡΡΡΠΎΠΉΡΠΈΠ²ΡΠΉ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΡΠ²Π΅Ρ ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ.ΠΠΎΠ½ΠΈΡΠΎΡΠΈΡΡΠ΅ΠΌΠ°Ρ Π²ΠΈΡΡΡΠ½Π°Ρ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠ° ΡΠ΅ΡΠ΅Π· 14 ΡΡΡΠΎΠΊ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π΅ ΡΡΠ³ΡΠ°Π»Π° ΡΠΎΠ»ΠΈ Π² ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠ°Π½ΡΠΎΠ² Π½Π° ΡΡΠΏΠ΅Ρ
Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΊΠΎΡΠΎΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π΄ΠΎ 12 Π½Π΅Π΄Π΅Π»Ρ ΠΊΡΡΡΠ° Β«ΡΡΠΎΠΉΠ½ΠΎΠΉΒ» ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅Π»Π°ΠΏΡΠ΅Π²ΠΈΡΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠ΅ Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΡ 100% ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ β Π°Π²ΠΈΡΠ΅ΠΌΠΈΠΈ ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ ΠΏΠΎΡΠ»Π΅ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ²Π΅Π½Π°Π΄ΡΠ°ΡΠΈΠ½Π΅Π΄Π΅Π»ΡΠ½ΡΠΉ ΠΊΡΡΡ Β«ΡΡΠΎΠΉΠ½ΠΎΠΉΒ» ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΡΠ΅Π»Π°ΠΏΡΠ΅Π²ΠΈΡΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΠΌ Π΄Π»Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΡΠ΅ΡΠ΅Π· 12 Π½Π΅Π΄Π΅Π»Ρ ΠΏΠΎΡΠ»Π΅ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΡΠ°Π½Π΅Π΅ Π½Π΅ Π»Π΅ΡΠ΅Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ 1-Π³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° ΠΈΠ»ΠΈ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠΌ ΠΏΠΎΡΠ»Π΅ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΊΡΡΡΠ° ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π‘Π‘ IL28B Π½Π° Π½Π°ΡΠ°Π»ΡΠ½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΏΡΠΈ ΡΡΠ»ΠΎΠ²ΠΈΠΈ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ Π±ΡΡΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ°, Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²ΡΡΠΎΠΊΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠ¦Π